Literature DB >> 7780967

Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2).

R Fridman1, M Toth, D Peña, S Mobashery.   

Abstract

The M(r) 72,000 (MMP-2; gelatinase A) and M(r) 92,000 (MMP-9; gelatinase B) gelatinases are two members of the family of matrix metalloproteinases (MMPs). These proteinases are thought to play a critical role in tumor cell invasion and are frequently coexpressed in human cancers. Gelatinases are secreted in a latent inactive form, and their conversion to the active species can be accomplished by other proteolytic enzymes, including other MMPs. We report herein that organomercurial or plasma membrane-activated M(r) 72,000 gelatinase A activates progelatinase B to an M(r) 82,000 active form in a process inhibited by tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. Progelatinase B activation was accomplished by the two active species of gelatinase A, the M(r) 62,000 and M(r) 45,000 forms, generated after plasma membrane or organomercurial activation of TIMP-2-free progelatinase A. The M(r) 45,000 species of gelatinase A lacks both the NH2-terminal profragment and the COOH-terminal domain known to play a role in plasma membrane activation and the regulation of TIMP-2 inhibition. These results suggest a novel mechanism of activation of progelatinase B mediated by gelatinase A species that may be localized in the surface of tumor cells and enhance matrix degradation during cancer metastasis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7780967

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  82 in total

1.  Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system.

Authors:  Y Jo; J Yeon; H J Kim; S T Lee
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

2.  MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits.

Authors:  A M Tester; N Ruangpanit; R L Anderson; E W Thompson
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

3.  Membrane type-1 matrix metalloproteinase (MT1-MMP) correlates with the expression and activation of matrix metalloproteinase-2 (MMP-2) in inflammatory breast cancer.

Authors:  Diaa Al-Raawi; Helal Abu-El-Zahab; Mohamed El-Shinawi; Mona Mostafa Mohamed
Journal:  Int J Clin Exp Med       Date:  2011-10-11

Review 4.  Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction.

Authors:  Merry L Lindsey; Rogelio Zamilpa
Journal:  Cardiovasc Ther       Date:  2010-07-14       Impact factor: 3.023

5.  Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1.

Authors:  E Levi; R Fridman; H Q Miao; Y S Ma; A Yayon; I Vlodavsky
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

Review 6.  Cystatin superfamily.

Authors:  Josiah Ochieng; Gautam Chaudhuri
Journal:  J Health Care Poor Underserved       Date:  2010-02

7.  Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue.

Authors:  Zhong Dong; R Daniel Bonfil; Sreenivasa Chinni; Xiyun Deng; J Carlos Trindade Filho; Margarida Bernardo; Ulka Vaishampayan; Mingxin Che; Bonnie F Sloane; Shijie Sheng; Rafael Fridman; Michael L Cher
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

8.  The role of matrix metalloproteinase-9 in negative reinforcement learning and plasticity in alcohol dependence.

Authors:  Bok Soon Go; Sunil Sirohi; Brendan M Walker
Journal:  Addict Biol       Date:  2019-01-16       Impact factor: 4.280

9.  Matrix metalloproteinase inhibitor, MMI270 (CGS27023A) inhibited hematogenic metastasis of B16 melanoma cells in both experimental and spontaneous metastasis models.

Authors:  Tatsuhiko Kasaoka; Hiroko Nishiyama; Mikiko Okada; Motowo Nakajima
Journal:  Clin Exp Metastasis       Date:  2008-07-31       Impact factor: 5.150

10.  Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors.

Authors:  K Lampert; U Machein; M R Machein; W Conca; H H Peter; B Volk
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.